CONSTANT LEVERAGE LONG - UCB Stock

C0EOB

FRBNPP06MX37

Market Closed - Euronext Paris 12:30:00 2024-06-19 pm EDT
8.655 ^EUR	+0.29%

Current month	+26.14%
1 month	+35.49%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : Financial Reporting Document	Jun. 15	PU
UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels	Jun. 13	CI
UCB : Financial Reporting Document	Jun. 13	PU
UCB to Share First Presentations of BIMZELX®? (bimekizumab-bkzx) Two-Year Data in Axial Spondyloarthritis and Psoriatic Arthritis at EULAR 2024	Jun. 12	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-19	8.655	+0.29%
24-06-18	8.63	+2.98%
24-06-17	8.38	-1.12%
24-06-14	8.475	+4.37%
24-06-13	8.12	+1.12%

Real-time Euronext Paris

Last update June 19, 2024 at 12:30 pm EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	UCB
Issuer	BNP Paribas
	C0EOB
ISIN	FRBNPP06MX37
Date issued	2024-03-27
Maturity	Unlimited
Parity	1 : 1
Emission price	5 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	8.685 €
Lowest since issue	4.737 €
Spread	0.45 €
Spread %	5.07%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

139 EUR

Average target price

135.5 EUR

Spread / Average Target

-2.56%

Consensus